Enhertu Double Approval, Regeneron Miss: What It Means for Smaller Biotechs

Two FDA decisions landed on the same Monday and pulled the sector in opposite directions. AstraZeneca and Daiichi Sankyo’s Enhertu picked up two new approvals in early breast cancer. Regeneron dropped 12% after its melanoma trial missed statistical significance against Keytruda. One validated a platform that smaller biotechs are actively building on. The other confirmed that Merck’s checkpoint inhibitor franchise is as close to untouchable as anything in oncology right now. Underneath both stories, selective capital kept moving into radiopharmaceuticals, immune disease, and rare disease plays that know exactly what their regulatory designations are worth in the current market.

The ADC platform gets its biggest validation yet

Enhertu received FDA approval on May 18 for both the neoadjuvant and adjuvant treatment of HER2-positive early breast cancer. That is its fifth and sixth breast cancer indications in seven years, backed by the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials. AstraZeneca triggered $155 million in milestone payments to Daiichi Sankyo on the same day. In the neoadjuvant setting, Enhertu delivered meaningfully improved pathologic complete response rates over standard chemotherapy. In the adjuvant setting, it targeted patients with residual invasive disease after standard treatment, a population with limited options and a well-documented recurrence risk.

Six indications across both early and metastatic HER2-positive breast cancer is the kind of breadth that defines a platform, not just a drug. The mechanism behind it is the antibody-drug conjugate (ADC), a targeted therapy that combines a tumor-seeking antibody with a cytotoxic payload, delivering treatment directly to cancer cells while limiting damage to healthy tissue. Enhertu proved that mechanism works at scale across multiple disease stages. That proof matters well beyond AstraZeneca and Daiichi Sankyo.

Multiple smaller biotechs are developing ADC candidates in overlapping indications and adjacent tumor types. When a platform gets this kind of clinical and regulatory endorsement, acquisition interest in smaller ADC developers accelerates. Larger players with capital to deploy and pipelines to fill start looking down the value chain for programs with differentiated payloads or novel target combinations. The M&A window in this space is open, and a double approval of this magnitude just made it wider.

Keytruda holds its moat

Regeneron’s Phase 3 melanoma trial of fianlimab in combination with Libtayo missed its primary endpoint against Keytruda on May 15, with markets absorbing the news on May 18. REGN fell more than 10% at the open and settled around $620, its lowest level since October. Analysts at BMO Capital Markets and Evercore ISI both removed fianlimab from their models. Between them, those models had pencilled in $900 million to $1.8 billion in risk-adjusted peak sales.

The clinical picture is complicated. The high-dose fianlimab combination held tumors in check for a median of 11.5 months versus 6.4 months on Keytruda, numerically better, with a p-value of 0.0627 that came close. BMO analysts noted the statistical miss was driven by a late separation in the progression-free survival curves. Regeneron still has a second Phase 3 trial running, comparing fianlimab against Bristol Myers Squibb’s Opdualag. Both BMO and Evercore said they have low confidence in a positive outcome from that study.

For smaller oncology companies, the structural read is clear. Keytruda’s first-line dominance is not a wall that a numerically better but statistically marginal result can break. Smaller checkpoint inhibitor programs trying to compete in the same space need a genuinely differentiated mechanism, a specific patient population Keytruda does not serve well, or a combination strategy with a clearly additive effect. The Regeneron result narrows the field of credible approaches and concentrates investor attention on the programs that have actually found that differentiation. It also puts Regeneron’s pipeline under pressure, which typically accelerates M&A appetite.

The PRV market is real

Fortress Biotech’s subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV), a transferable designation awarded by the FDA to companies that gain approval for drugs treating rare pediatric conditions. The holder can use it to receive an accelerated six-month FDA review for a future drug application, or sell it to another company. The sale price was $205 million, following the FDA approval of ZYCUBO for Menkes disease. Fortress used part of the proceeds to cut its outstanding debt with Oaktree to $15 million.

The PRV market has been active for years but the price point matters. $205 million is what a rare pediatric disease voucher is worth in the current environment. For a small biotech developing a drug for a rare childhood condition, often a population too small to generate meaningful commercial revenue on its own, that number changes the entire investment case. The program does not need to be a blockbuster. FDA approval alone, even in a small patient population, can generate $200 million or more from the voucher sale independent of the drug’s commercial trajectory.

Smaller biotechs with FDA orphan drug or rare pediatric disease designations in their pipeline are sitting on an asset the market often underprices. Fortress just put a number on what it is worth. That is a blueprint investors in the rare disease space should be running through their portfolio right now.

Where selective capital is moving

Full-Life Technologies, a radiopharmaceuticals developer, and Accro Bioscience, focused on immune diseases, raised $160 million combined in equity financings announced May 19. Bristol Myers Squibb’s licensing deal with Hengrui was the second-largest pact of its kind since early 2025, trailing only AstraZeneca’s $18.5 billion CSPC tie-up from January. Capital is moving. It is moving selectively.

The pattern is consistent across all of this week’s activity. Money is going into platforms with differentiated mechanisms, radiopharmaceuticals, novel immune targets, rare disease, and into companies with clean regulatory positioning and a clear path to a meaningful data readout. It is not going into programs chasing entrenched blockbusters without a clear edge, and it is not going into commodity oncology without a compelling answer to the Keytruda question.

For smaller biotechs watching the funding environment, that is a precise signal. Differentiated mechanism or validated rare disease designation gets you in the door. Neither is sufficient without the data to back it up. But the companies that have both, a novel platform and a credible regulatory pathway, are finding capital available in a market that is otherwise getting more selective by the quarter.

What to Watch

Biogen’s BIIB080: cleared for Phase 3 in Alzheimer’s based on Phase 2 biomarker and efficacy data. Late-stage readout will be one of the bigger catalysts in the space whenever it arrives. Watch for trial design details and enrollment timelines.

Regeneron’s second fianlimab trial: the head-to-head against Opdualag is still running. If that study also misses, it closes the melanoma chapter for fianlimab entirely and likely reopens M&A conversations around Regeneron’s broader oncology assets.

ADC M&A pipeline: with Enhertu’s double approval reinforcing the platform thesis, watch for acquisition or licensing activity targeting smaller ADC developers with differentiated payloads. This is the most active M&A thesis in oncology right now.

PRV market: any further voucher sales in Q2 will either confirm or adjust the $205 million benchmark Fortress just set. Smaller rare disease developers with pending approvals should be watching this number closely.

Sources

Editorial Disclosure

This analysis is based entirely on publicly available information including press releases, regulatory filings, and clinical trial disclosures. Securities discussed include AstraZeneca PLC (Nasdaq: AZN), Daiichi Sankyo Co. Ltd. (OTC: DSKYF), Regeneron Pharmaceuticals Inc. (Nasdaq: REGN), Merck & Co. Inc. (Nasdaq: MRK), Bristol Myers Squibb Co. (NYSE: BMY), and Fortress Biotech Inc. (Nasdaq: FBIO). aktiego.com has not received any compensation from any company mentioned, their management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in any security mentioned at the time of publication. All information is sourced from named public filings on SEC EDGAR and company press releases via named wire services. FDA approval status for all drugs referenced is clearly distinguished from investigational or trial-stage compounds. Clinical data referenced is caveated to the specific study populations in which it was generated and does not constitute medical advice. Forward-looking commentary regarding M&A activity, regulatory outcomes, and market developments is opinion only. Microcap and smaller-operator references are included for market context only and do not constitute investment recommendations. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.

Enhertu Double Approval, Regeneron Miss: What It Means for Smaller Biotechs

Join our Mailing List